Ben Caplin et al. (Caplin et al., 2012) provided strong evidence that alanine-glyoxylate aminotransferase-2 (AGXT2) metabolizes endogenous methylarginines in vivo, and disruption of this enzyme also leads to reduced NO bioavailability and hypertension. This evidence concerns the gene AGXT2 and hypertensive disorder.